The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Precision Cancer Therapy in Rare Cancers
Official Title: The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers
Study ID: NCT06119789
Brief Summary: Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Detailed Description: All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Åslaug Helland, MD PhD
Affiliation: Oslo University Hospital
Role: PRINCIPAL_INVESTIGATOR